Sustained virologic response improved the long-term health-related quality of life in patients with chronic hepatitis C: a prospective national study in China
- PMID: 38200419
- PMCID: PMC10782531
- DOI: 10.1186/s12879-023-08940-3
Sustained virologic response improved the long-term health-related quality of life in patients with chronic hepatitis C: a prospective national study in China
Abstract
Background: To investigate the trends in health-related quality of life (HRQoL) among hepatitis C virus (HCV) patients and to assess the longitudinal impact of antiviral therapy on their well-being.
Methods: In this prospective multicenter observational study in adults with HCV infection, sociodemographic, clinical characteristics and EQ-5D questionnaires were collected. Generalized estimating equation (GEE) models were used to assess the associations between these variables and changes in HRQoL over time.
Results: 456 patients were included, with a median age of 46.5 (36.5-57.0) years, of which 262 (57.5%) were males and 44 (9.6%) had cirrhosis. 335 patients (73.5%) receiving antiviral therapy and 61.8% achieved sustained virologic response (SVR). The baseline EQ-5D utility and EQ-VAS were 0.916 ± 0.208 and 80.6 ± 13.0. In multivariable analysis of GEE estimation, achieving SVR24 was positively associated with EQ-5D utility (p = 0.000) and EQ-VAS (p = 0.000) over time. Age and income were shown to be significant predictors of EQ-5D utility, while gender, age and genotype were associated with EQ-VAS over time.
Conclusions: SVR improved long-term HRQoL in HCV patients in the first few years following viral clearance. Certain sociodemographic factors, such as gender, age, income as well as genotype, significantly influenced long-term changes in patients' quality of life.
Trial registration: NCT01594554. Registration date: 09/05/2012.
Keywords: Health-related quality of life (HRQoL); Hepatitis C virus (HCV); Sustained virological response (SVR).
© 2024. The Author(s).
Conflict of interest statement
LW has received research grants from Abbvie, Bristol-Myers Squibb, and Gilead, and consulting for Gilead, Huahui, MSD, Pfizer, speaker for Ascletis Pharma, Bristol- Myers Squibb, Gilead, and Kaiyin. HR has received a speaker honorarium from Bristol-MyersSquibb, Gilead, and AbbVie. Other authors declare that they have no competing interests.
Figures
Similar articles
-
Impact of successful treatment with direct-acting antiviral agents on health-related quality of life in chronic hepatitis C patients.PLoS One. 2018 Oct 9;13(10):e0205277. doi: 10.1371/journal.pone.0205277. eCollection 2018. PLoS One. 2018. PMID: 30300395 Free PMC article.
-
A cross-sectional assessment of health-related quality of life in Chinese patients with chronic hepatitis c virus infection with EQ-5D.Health Qual Life Outcomes. 2018 Jun 15;16(1):124. doi: 10.1186/s12955-018-0941-8. Health Qual Life Outcomes. 2018. PMID: 29903024 Free PMC article.
-
Factors Associated with Health-Related Quality of Life in Korean Patients with Chronic Hepatitis C Infection Using the SF-36 and EQ-5D.Gut Liver. 2018 Jul 15;12(4):440-448. doi: 10.5009/gnl17322. Gut Liver. 2018. PMID: 29588435 Free PMC article.
-
Long-term changes on health-related quality of life in patients with chronic hepatitis C after viral clearance with direct-acting antiviral agents.Rev Esp Enferm Dig. 2019 Jun;111(6):445-452. doi: 10.17235/reed.2019.6063/2018. Rev Esp Enferm Dig. 2019. PMID: 31066286
-
Health state utility values measured using the EuroQol 5-dimensions questionnaire in adults with chronic hepatitis C: a systematic literature review and meta-analysis.Qual Life Res. 2019 Feb;28(2):297-319. doi: 10.1007/s11136-018-1992-3. Epub 2018 Sep 17. Qual Life Res. 2019. PMID: 30225787
Cited by
-
Cryptogenic cirrhosis: Decoding diagnostic challenges through radiological insights.Radiol Case Rep. 2024 Apr 19;19(7):2735-2740. doi: 10.1016/j.radcr.2024.03.069. eCollection 2024 Jul. Radiol Case Rep. 2024. PMID: 38680743 Free PMC article.
-
Impact of a minimal monitoring HCV treatment approach on Health-Related Quality of Life.Qual Life Res. 2025 Jun;34(6):1683-1694. doi: 10.1007/s11136-025-03922-1. Epub 2025 Feb 28. Qual Life Res. 2025. PMID: 40019678
References
-
- WHO, Global hepatitis report. 2017. https://apps.who.int/iris/bit, 2020.
-
- Ghany MG, Morgan TR. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and treating Hepatitis C virus Infection. Hepatology. 2020;71:686–721. doi: 10.1002/hep.31060. - DOI - PMC - PubMed
-
- EASL recommendations on treatment of hepatitis C Final update of the series(☆) J Hepatol. 2020;73:1170–218. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical